“Draft:Natco Pharma Ltd”的意思、由来-开放百科全书

The main areas of work — the development of drugs to combat viral (including hepatitis C) and cancer.

Natco Pharma operates in India, USA, Europe and Asia. Subsidiaries are located in North and Latin America, Asia Pacific, the middle East and South-East Asia.

The company was originally called Natco Fine Pharmaceutical Ltd. It became officially public in July 1992. In February 1993, it changed its name to Natco Pharma (NPL).^[1]

The range of products Natco Pharma Limited is pharmaceutical more than 500 titles and is constantly expanding thanks to the fundamental research and cooperation in the field of technology.^[2]

The company produces drugs such as Sofosbuvir, Daclatasvir, Lenalidomide, Entecavir, Deferasirox, Ledipasvir, Imatinib, Bendamustine, Bortezomib, Chlorambucil, Velpatasvir etc.

NPL is a manufacturer of medicinal products for Ranbaxy and Park Davis companies and holds ISO 9002 certification, which allows to develop exports. Natco Pharma Ltd has initiated drug registration procedures under its own brand in more than 20 countries.

To enter the us market, NPL formed a subsidiary of Natco Pharma in the US and entered into research cooperation with the regional research laboratory in Jammu, the center for cell and molecular biology for synthetic peptides and the Central Institute for skin research.

Natco Laboratories, Natco Parenterals and Karanth Pharmaceuticals have teamed up with the flagship company NPL to provide a large asset base and increase high-tech capabilities.^[3]

Location

Representative offices in other countries

Company management

Company history

The company started its activity in 1981. Today, it has its own research centers and more than 4,000 qualified scientists. NPL products are exported to the USA, Australia, Canada, Brazil, Europe, CIS countries, Vietnam, Hong Kong, China, Netherlands, Nigeria, Tanzania and Kenya, etc.

Natco Pharma Limited is certified by the world health organization and manufactures products for Ranbaxy Laboratories Ltd., Eskayef Ltd., Park Davis (I) Ltd., Fulford India Limited, Cadila Ltd., John Wyeth India Ltd., ICI Ltd. and SOL Pharmaceuticals Ltd.^[5]

Chronology

1997 — Natco Pharma Limited entered into an agreement granting the right to sell Natco products in Russia and other CIS countries. Merger of group companies — Natco Pharma Natco Laboratories Natco Parenterals and Dr.Karanth Pharma Chemical Labs.

1998 — Natco Pharma Ltd entered into an agreement with the American pharmaceutical giant Mallin Krodt for the production and export of Naproxen.

2002 — Natco Pharma Ltd has received approval from the therapeutic goods Administration (TGA), Australia for its manufacturing facility in Macague.

Release of the drug containing Zoledronic acid for injection. Natco Pharma became the second company to launch the production of this medicine in the world.

Release of Letrozole for the treatment of advanced breast cancer in postmenopausal women.

Order Rs 35-fr for export of Citalopram Hydrobromide (used for treatment as antidepressant).

2004 — Natco Pharma launches cancer drug, opens Oncology division. In the same year produces a drug for the treatment of prostate cancer and a drug for ovarian cancer.

2005 — Natco Pharma Limited signs Memorandum of understanding (MoU) for the exchange of technologies related to the production of cancer products. Also starts the drug Voriconazole.

2006 — Natco announces the launch of Pemetrexed for the treatment of non-small cell lung cancer.

2011 — Natco together with the American company Levomed LLS formed another company Natcofarma Do Brasil for the distribution of medicines in Brazil.

2012 — the company for its development receives the world prize "Golden peacock".

Pricing policy of the company

Natco Pharma Ltd produces analogues of expensive, well-known, branded medicines, making them available to low-income patients. So, in 2012, the Indian company has cancelled the patent for a cancer drug made by Bayer, stating that he was going to sell generic drugs Tosylate of Sorafenib for 3 percent of the price charged by Bayer from Germany for the original. Today Natco sells the drug in India for $ 174. The original drug Bayer sells for $ 5,500.^[9]^[10]^[11]

In 2015, Natco under Its own brand released Sofosbuvir-a drug that is used to treat chronic hepatitis C — an analogue of the drug "Sovaldi" ("Sovaldi"), which is produced by the American company Gilead. The price for a bottle of medicine is set at about 20 thousand rupees, which is about 300 dollars. A 12-week course costs about 945 dollars (that is 12 times cheaper than the original in the US).^[12]

In may 2017, the Indian company has produced a cure for blood cancer for the price of 5 000-20 000 rupees, which is 98 % below the price in the United States.^[13] Pomalidomide is intended for patients with multiple myeloma (a type of blood cancer). The drug is sold by Celgene Inc in the United States under the brand name "Pomalyst". Natco will sell pomalidomide capsules under its own brand in India.^[14]

In October 2017, the shares of Natco Pharma Ltd rose by 20 %^[15], as the us food and drug administration (FDA) approved the generic drug Copaxone developed by Natco in partnership with the Dutch company Mylan. Is a medicine used for the treatment of multiple sclerosis. The original drug is produced and sold by the Israeli company Teva. For 12 months to 31 July 2017, the volume of sales of Copaxone in the dosage of 20 mg amounted to 700 million dollars, in the dosage of 40 mg-3.6 billion dollars.^[16]

References

1. ^¹{{Cite web|url=https://www.forbes.com/companies/natco-pharma/|title=«Asia's 200 Best Under A Billion 2017 RANKING»|author=|first=|date=2017-07-17|website=Internet-version of "Forbes"|publisher=|archive-url=|archive-date=|dead-url=|access-date=}}
2. ^{{Cite web|url=https://www.bloomberg.com/quote/NTCPH:IN|title=«About Natco Pharma Ltd»|author=|website=Bloomberg.com - Официальный сайт издания финансовой информации для профессиональных участников финансовых рынков|date=|publisher=}}
3. ^¹{{Cite web|url=http://www.business-standard.com/company/natco-pharma-4684/information/company-history|title=«NATCO PHARMA LTD. (NATCOPHARM) - COMPANY HISTORY»|author=|website=business-standard.com, официальный сайт газеты Business Standard|date=|publisher=}}
4. ^{{Cite web|url=http://www.moneycontrol.com/india/stockpricequote/pharmaceuticals/natcopharma/NP07|title=«Natco Pharma Ltd.»|author=|website=moneycontrol.com - новостное издание, сайт онлайн-трейдинга|date=|publisher=}}
5. ^¹{{Cite web|url=https://economictimes.indiatimes.com/natco-pharma-ltd/infocompanyhistory/companyid-8305.cms|title=«Company History - Natco Pharma Ltd»|author=|website=The Economic Times, официальный сайт ежедневной газеты.|date=|publisher=}}
6. ^{{cite journal |author = Ganapati Mudur |editor= |format= |url= |title= Indian health groups welcome country’s first compulsory licence |type= |origyear= | agency = |edition= BMJ: British Medical Journal |location= |date= March 2012 |publisher= |at= |volume= |issue= |number= 344|pages = 6 |page= |series= |isbn = |issn = |doi = |bibcode = |arxiv = |pmid = |ref= |archiveurl = |archivedate = |language= |quote= 24 }}
7. ^{{cite journal |author = Enrico Bonadio |editor= |format= |url= |title= India Grants a Compulsory Licence of Bayer's Patented Cancer Drug: The Issue of Local Working Requirement |type= |origyear= | agency = |edition= European Journal of Risk Regulation |location= |date= |year= 2012 |publisher= |at= |volume= 3 |issue= |number= 2|pages = 247—250 |page= |series= |isbn = |issn = |doi = |bibcode = |arxiv = |pmid = |ref= |archiveurl = |archivedate = |language= |quote= }}
8. ^{{Cite web|url=https://www.thepharmaletter.com/article/bayer-cancer-drug-faces-new-nexavar-patent-problems-in-india|title=«Bayer cancer drug faces new patent problems in India»|author=|website=www.thepharmaletter.com - Новостное, аналитическое агентство в области медицины, дженериков и биотехнологий.|date=2017-04-10|publisher=}}
9. ^{{Cite web|url=http://www.business-standard.com/article/news-cm/natco-pharma-launches-hepcinat-in-nepal-115030900103_1.html|title=«Natco Pharma launches HEPCINAT in Nepal»|author=|website=Онлайн-версия газеты Business Standard|date=2015-03-10|publisher=}}
10. ^{{cite journal |author = Губина М.А. |editor= |format= |url= http://worldec.ru/content/articles/12-02-2013_%D0%A1%D1%82%D0%B0%D1%82%D1%8C%D1%8F%20%D1%80%D0%B0%D1%81%D1%88%D0%B8%D1%80%D0%B5%D0%BD%D0%BD%D0%B0%D1%8F_%D0%98%D0%BD%D0%B4%D0%B8%D1%8F.pdf |title= Влияние присоединения к ВТО на фармацевтическую отрасль: опыт Индии, возможные последствия для России |type= |origyear= | agency = |edition= монография «Членство в ВТО – новый этап участия России в международной торговой системе». / Под ред. С.Ф. Сутырина и Н.А. Ломагина. СПб: ЭФ СПбГУ – 256 с |location= |date= |year= 2013 |publisher= |at= |volume= |issue= |number= |pages = 120—135 |page= |series= |isbn = |issn = |doi = |bibcode = |arxiv = |pmid = |ref= |archiveurl = |archivedate = |language= |quote= }}
11. ^{{cite journal |author = Oguanobi HI. |editor= |format= |url= https://onlinelibrary.wiley.com/doi/abs/10.1111/jwip.12091 |title= Broadening the conversation on the TRIPS agreement: Access tomedicines includes addressing access to medical devices. |type= |origyear= | agency = |edition= J World Intellect Prop. |location= |date= |year= 2018 |publisher= |at= |volume= |issue= |number= 21|pages = 70–87 |page= |series= |isbn = |issn = |doi = |bibcode = |arxiv = |pmid = |ref= |archiveurl = |archivedate = |language= |quote= }}
12. ^{{Cite web|url=https://life.ru/t/%D0%B7%D0%B4%D0%BE%D1%80%D0%BE%D0%B2%D1%8C%D0%B5/923190/amierikanskii_farmghighant_ghotov_spasti_rossiiu_ot_ghiepatita|title=«Американский фармгигант готов спасти Россию от гепатита»|author=Александра Рыкова|website=Информационный портал Life.ru|date=2016-10-31|publisher=}}
13. ^{{Cite web|url=http://www.firstpost.com/business/natco-pharma-launches-blood-cancer-drug-priced-rs-5000-20000-down-98-from-us-price-3436186.html|title=«Natco Pharma launches blood cancer drug priced Rs 5,000-20,000, down 98% from US price»|author=|website=Новостной портал firstpost.com|date=2017-05-10|publisher=}}
14. ^{{Cite web|url=http://www.livemint.com/Companies/AW76LSaHwTw4wo3CB7Ye7K/Natco-Pharma-launches-generic-blood-cancer-drug-in-India.html|title=«Natco Pharma launches generic blood cancer drug in India»|author=|website=Онлайн-издание деловой газеты Livemint|date=2017-05-10|publisher=}}
15. ^{{Cite web|url=https://www.finam.ru/analysis/marketnews/bychiiy-nastroiy-v-indii-soxranyaetsya-20171004-13450/|title=«Бычий» настрой в Индии сохраняется»|author=|website=Официальный сайт инвестиционной группы «ФИНАМ»|date=2017-10-04|publisher=}}
16. ^{{Cite web|url=https://www.pharmvestnik.ru/publs/lenta/v-mire/fda-odobrilo-analog-preparata-copaxone.html#.WjEM_lVl82x|title=«FDA одобрило аналог препарата Copaxone»|author=|website=Фармацевтический вестник pharmvestnik.ru|date=2017-10-04|publisher=}}